Elequin Capital’s Moderna MRNA Stock Holding History

Elequin Capital’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-135	Closed	-$6.86K	–	839
2026 Q1	$6.86K	Buy	+135	New	+$6.3K	﹤0.01%	363

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Elequin Capital's MRNA Position: Q2 2026 in Review

Elequin Capital sold out of Moderna (MRNA) in Q2 2026, closing a stake of 135 shares — an estimated $6.86K sold.

Elequin Capital first reported a position in MRNA in Q1 2026 and held it in 1 quarter. The position peaked at $6.86K in Q1 2026. 784 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Elequin Capital reported no remaining Moderna position as of Q2 2026 after selling out during the quarter.
Elequin Capital sold 135 Moderna shares in Q2 2026, an estimated $6.86K.
Elequin Capital first reported a position in Moderna in Q1 2026 and held it in 1 quarter.
Elequin Capital's Moderna position peaked at $6.86K in Q1 2026.
784 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Elequin Capital's 13F filing for Q2 2026, filed 13 Aug 2026.